Omeros (OMER) said Wednesday the US Food and Drug Administration has approved Yartemlea to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, a complication of stem-cell transplants.

Shares of the healthcare firm increased nearly 80% as intraday trading volume jumped to nearly 20.7 million, versus a daily average of roughly 3.7 million.

Edgewise Therapeutics (EWTX) rose roughly 21% after the company said it completed parts B and C of a phase 2 trial of EDG-7500 in patients with obstructive and nonobstructive hypertrophic cardiomyopathy and reported favorable interim safety results from its ongoing part D study.

Trading volume rose to 2.5 million from a daily average of about 1.3 million.

Sanofi (SNY) on Wednesday agreed to buy infectious disease vaccine maker Dynavax Technologies (DVAX) in a deal with an equity value of about $2.2 billion, as the company aims to strengthen its adult immunization portfolio.

Shares of Dynavax Technologies gained about 38% as intraday trading volume climbed to about 24.8 million from a daily average of about 1.6 million.

Price: 26.34, Change: +4.59, Percent Change: +21.13